2004
Michael Abràmoff, MD, PhD, joins University of Iowa Carve College of Medicine as assistant professor in ophthalmology and visual sciences.
2005
Abràmoff receives faculty appointment in UI College of Engineering.
2010
AI diagnostics company IDx launched by Abràmoff, as president and founder, with collaborators and several colleagues in UI Department of Ophthalmology and Visual Sciences.
2013
IDx-DR, an autonomous AI diagnostic system that detects diabetic retinopathy, approved for marketing in Europe.
2017
January
Clinical trial of IDx-DR launches in primary care sites around the U.S.
February
IDx joins IBM Watson Health Medical Imaging Collaborative, which includes health systems, private practices, and AI companies developing cognitive imaging solutions for various health challenges.
October
Abràmoff participates in U.S. Senate and House of Representatives briefings in Washington, D.C., on accelerating development of health care innovations.
2018
February
IDx files De Novo submission to Food and Drug Administration for expedited review of IDx-DR, which earlier was granted an FDA “Breakthrough Device” designation—a classification reserved for technologies that “provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition.”
April
IDx-DR earns FDA clearance.
June
ID x-DR debuts at Diabetes and Endocrinology Center at UI Health Care–Iowa River Landing in Coralville, Iowa.
August
Results of clinical trial of IDx-DR published in Nature Digital Medicine.
UI Hospitals & Clinics rated No. 7 for ophthalmology among America’s “Best Hospitals” by U.S. News & World Report, which consistently ranks the department in the nation’s top 10.
September
IDx secures $33 million in venture capital funding to develop more diagnostic systems for its AI platform.
•